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A B S T R A C T
This study compared Triclosan coated polyglactin 910 (Vicryl* Plus) with polyglactin 910(Vicryl*) on abdominal
wall healing in colorectal surgery patients. 184 patients with colorectal cancer were included in the study. In 91, the ab-
dominal wall was closed with the Vicryl* Plus, and in 93 patients with Vicryl*. Demographic characteristics, biochemi-
cal inflammatory parameters, wound appearance, length of hospital stay, postoperative wound complications and post-
incisional hernia were recorded. In the Vicryl* Plus group there was a shorter hospital stay (13.2±1.3 days; 21.4±2.8
respectively). In the Vicryl* Plus group inflammatory parameters decreased to normal within the first week whereas in
the Vicryl* group remained increased. In the Vicryl* Plus group four patients had a wound discharge, seven had inflam-
matory reactions to the skin sutures. One dehiscence was noticed. In the Vicryl* group 12 patients had an SSI, 14 pa-
tients had inflammatory reactions to the skin sutures and 7 patients had a wound dehiscence. Closure of the abdominal
wall using Vicryl*Plus decreases postoperative wound complications, length of hospital stay and is associated with a
more rapid return of inflammatory markers to normal.
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Introduction
Development of infection in incisional wounds and
poor healing represent the most common complications
of abdominal surgery which may also include serious life
threatening complications. These complications are es-
pecially dangerous in high risk patients. Some patients
are operated on electively after adequate preoperative
preparation. All surgical site complications cause higher
mortality, higher morbidity and extra hospital days for
those patients. Many intrinsic and extrinsic risk factors
may influence the process of wound healing such as skin
antisepsis, operative technique, antimicrobial prophy-
laxis, gender, BMI and prior operative procedures1–3.
During the past 20 years surgeons have standardized
preoperative, intraoperative and postoperative procedu-
res to maximise the reduction of surgical site infections
(SSIs). All these procedures, such as correction of nutri-
tional disorders and preoperative and postoperative pro-
tein status, antibiotic prophylaxis, skin antiseptic prepa-
ration, and adequate operative techniques are documen-
ted. Those procedures reduce the risk of intraoperative
and SSIs, and significantly improve patients’ outcomes.
The influence of the suture material on SSIs has been
developed over the last 50 years4,5. During that period
surgeons have shown that surgical sutures, like any
other implant in human body, can cause microbial adher-
ence and colonization. Various microorganisms may con-
taminate wounds posroperatively and suture material.
When the sutured material becomes contaminated, local
mechanisms of wound decontamination become ineffec-
tive6,7. Triclosan coated polyglactin 910 was developed to
prevent microbial colonization of suture material in op-
erative wounds. Some experimental published studies
have shown a decrease in bacterial adherence to triclosan
439
Received for publication January 21, 2011
coated suture in vitro and in vivo8–16. Those studies eval-
uated contaminated suture material in conditions made
to represent the surgical wound. The majority of these
studies were designed in vitro, and results suggested that
antibacterial-coated sutures show an inhibitory influ-
ence on bacteria placed in surgical wounds.
This current study was of clinical design and included
184 patients with colorectal carcinoma being operated on
electively. The aim of the study was to compare the effect
of triclosan coated polyglactin 910 (Vicryl* Plus) or poly-
glactin 910(Vicryl*) on abdominal wall healing in theese
patients.
Materials and Methods
In a 12-month period (September 2008–September
2009), 184 patients diagnosed with colo-rectal, cancer
scheduled for elective surgery, were included in the study.
Ethical approval was obtained and written consent was
provided by the participants.
All operations were performed in the Department of
Surgery, »Sveti Duh« University Hospital, Zagreb, Croa-
tia, by the same surgical team and the same anesthesiolo-
gist. Preoperative investigation included complete colo-
noscopy (with biopsy and histological confirmation of
cancer), chest X-ray, ultrasonography, CT scan and rele-
vant serum tests
All operations were performed through a midline inci-
sion. The skin was incised (15–18 cm length) with a scal-
pel; all other layers were transected with diathermy. Pro-
phylactic antibiotics, gentamicin 160 mg (Gentamicin,
Belupo, Koprivnica, Croatia) and metronidazole 500 mg,
(Medazol, Belupo, Koprivnica, Croatia) were given intra-
venously during induction of anaesthesia. Wound closure
was performed with a continuous single-layer mass tech-
nique (peritoneum, muscle, and fascia). 91 patients were
randomised to closure with 0 Vicryl* Plus (Ethicon John-
son-Johnson) and 93 patients with 0 Vicryl* (Ethicon
Johnson-Johnson).
Randomization was generated by a computer in blo-
cks of 10. Sealed and numbered opaque envelopes con-
taining suture packets were prepared. The envelopes
were kept in the operating theatre and assigned in order.
The running sutures were 1 cm apart and 1.5 cm from
the wound edge. Skin was closed with polyamide (Ethi-
lon, 2–0, Ethicon, Johnson-Johnson). Postoperative data
were collected from operation reports, nurses wound re-
ports, chart review and microbiology reports. The pa-
tients were carefully followed throughout their hospital-
ization by the same surgical team and were carefully
monitored with the following parameters: duration of op-
erative procedure, duration of hospitalization, biochemi-
cal inflammation parameters (white blood cell count –
WBC; procalcitonin – PCT; and C-reactive protein –
CRP), presence of wound infection, dehiscence, haema-
toma or inflammatory reactions to the skin sutures (skin
inflammation around the suture), postoperative hernias,
readmissions and reoperations.
Statistical analysis
Differences between groups were compared by the c2
or Fisher exact test for categorical variables, the Mann-
-Whitney U-test for continuously variables. Data inclu-
ded all biographic and perioperative data as well as post-
operative outcome. Results are given as absolute num-
bers, mean and standard deviation, or as median (range),
unless indicated otherwise. The two-sample Student’s
t-test was used to test the hypothesis of equality of
means. A p value < 0.05 was considered statistically sig-
nificant.
Results
During the 12-month period (September, 2008–Sep-
tember, 2009) 184 patients, having elective surgery for
colorectal cancer, were admitted to the study. 91 patients
were randomised to have closure of their abdominal wall
with Vicryl* Plus, and 93 patients with Vicryl.
Fifty three percent of the patients were male (99) and
47% (85) were female. Their mean age was 58±14.5 years
in the Vicryl* Plus group and 57±14.7 years in the Vicryl
group. The mean BMI of the patients was 22.7±1.6 in the
Vicryl* Plus group and 22.1±1. in the Vicryl group. There
was no statistical difference in demographic and preoper-
ative data between the two groups (Table 1).
The mean operation time was 95.5±17.3 min in the
Vicryl* Plus group and 91.3±15.3 min in the Vicryl
group. (Table1). The mean hospitalization period was
1.2±1.3 day in the Vicryl* Plus group and 21.4±2.8 in
the Vicryl group (p<0.05). There were no deaths in ei-
ther group.
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TABLE 1
DEMOGRAPHIC AND OPERATIVE DATA IN PATIENTS
OPERATED ON FOR COLORECTAL CANCER
Vicryl* plus Vicryl* p
Age(years) 58±14.5 57±14.7 0.9999
40–50 17 (19) 19 (21)
50–60 31 (34) 33 (35)
60–70 25 (27) 21 (23)
70–80 15 (17) 17 (18)
>80 3 (3) 3 (3)
Gender
m 49 (54) 50 (54)
f 42 (46) 43 (46)
BMI 22.7±1.6 22.1±1.4 0.9754
<20 13 (14) 13 (14)
20–25 70 (78) 71 (77)
>25 7 (8) 9 (9)
Duration of
surgery (min) 95.5±17.3 91.3±18.6
0.8933
data presented as n (%), significant differences (p<0.05) between
groups*
Inflammatory biochemical parameters
Values of inflammatory parameters at baseline were
not statistically significantly different between the two
groups. On the first postoperative day similar procalci-
tonin (PCT) (0.3±0.1 mg/L) values were found in both
groups. However, on the second day PCT increased in
both groups, but was statistically significantly lower in
the Vicryl* Plus group (p<0.05) and remained lower during
the first postoperative week (p<0.05). Thereafter the
PCT values normalized without any differences (Figure 1).
Leukocyte counts postoperatively were also increased
in both groups but fell continuously (without any signifi-
cance during first two postoperative days). However, af-
ter the second postoperative day significantly lower leu-
kocyte levels were found in the Vicryl* Plus group over
the next three days (p<0.05). After the seventh postoper-
ative day the leukocyte values were within normal range
in both groups (Figure 2).
CRP levels increased postoperatively in both groups
but then fell to normal levels. On the second postopera-
tive day significantly lower CRP values were found in the
Vicryl* Plus group which was maintained for the next
twelve days (p<0.05). CRP values had returned to nor-
mal in the Vicryl* Plus group by the fifth postoperative
day but did not return to normal in the Vicryl * group un-
til the 12th postoperative day (Figure 3).
Wound complications
Significantly less postoperative inflammatory reac-
tions to the skin sutures were seen in the Vicryl* Plus
group (7.5%), compared with the Vicryl* group (17.5%),
significantly less SSIs (4.3% in the Vicryl* plus group
compared with 13.2% in the standard Vicryl* group);
with less dehiscences (4.3% Vicryl* plus patients com-
pared with 13.2% in Vicryl* group). In 8.8% of the Vicryl*
group patients, re-operation was necessary (in 7 patients
because of wound dehiscence and in one patient because
of peritonitis) whereas only 1% needed re-operation in
the Vicryl* plus group (wound dehiscence). These differ-
ences in complication rates between groups is statisti-
cally significant (p<0.05). The difference between in-
cisional hernia incidence was not statistically significant
(5.5% in Vicryl* group compared with 2.2% in Vicryl*
plus group; p=0.235) (Table 2).
Discussion
Poor or delayed wound healing caused by infection in
incisional wounds is a serious problem after abdominal
surgery and it can be sometimes characterized as being
life threatening. The morbidity after SSI is expensive; re-
lating to treatment costs including antibiotics, prolonged
hospitalization, and loss of work productivity10.
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Fig. 1. Postoperative procalcitonin as a inflammatory marker. Data


















Fig. 2. Posroperative leukocyte counts. Data presented as X±SD,














Fig. 3. Posroperative CRP levels. Data presented as X±SD, sig-
nificant differences (p<0.05) between groups*.
TABLE 2
WOUND COMPLICATIONS
Vicryl plus Vicryl p
Inflammatory reactions to
skin sutures
7 (7.5) 16 (17.5) 0.039
Presence of wound infection 4 (4.3) 12 (13.2) 0.035
Dehiscence 1 (1.1) 7 (7.7) 0.027
Re operations 1 (1.1) 8 (8.8) 0.015
Incisional hernia 2 (2.2) 5 (5.5) 0.235
data are expressed as number (%) of patients, p<0.05 significant
differences between groups
Significant number of risk factors for inadequate wound
healing is well known. Recent studies have shown signifi-
cantly decreased number of SSIs after wound closure with
triclosan coated polyglactin suture (Vicryl* Plus)4–17.
Foreign material in wounds and tissue in general is re-
cognised to increase the susceptibility of surrounding tis-
sue to infection. It is an also known that contaminated
suture material inacyivates local mechanisms of wound
decontamination8. In consideration of this the develop-
ment of an antibacterial suture has been an aim for the
past two decades. Triclosan coated polyglactin 910 (Vi-
cryl* Plus) has been developed as a result. Triclosan is a
broad-spectrum antiseptic with documented safety and
efficacy. It has antiseptic activity against selected Gram
positive and Gram-negative bacteria8,18.
Few recent studies suggested that sub-inhibitory or
long term exposure to triclosan is not associated with di-
minished triclosan activity or increased antimicrobial
resistance19,20. Although these studies suggest that the
acquisition of microbial resistance to triclosan appears to
be very low based on minimal inhibitory concentration
data, it should be emphasized that selected microbial
populations (ie, Pseudomonas aeruginosa) have been found
to be resistant to various antiseptic agents, including
triclosan. There is potential risk of bacterial resistance to
triclosan activity8.
Several studies have investigated the antibacterial ac-
tivity of Vicryl* Plus in vitro and in vivo11–16 and shown
that it has no negative effect on wound healing17,20. It has
also been shown that triclosan-coated sutures are highly
effective in reducing the microbial adherence of both
biofilm-forming and non biofilm-forming staphylococcal
isolates to the surface of braided surgical sutures8.
Ford and colleagues reported in 2005 that triclo-
san-coated polyglactin sutures decreased postoperative
pain in paediatric patients21. No effect on wound healing
was observed.
Gomez-Alonso and others have shown, in an animal
model, that Vicryl* Plus antibacterial suture modulates
inflammatory response to levels similar to those ob-
served in uninfected wounds, with normalization of the
tissue healing process12.
Rozzelle and colleagues confirmed that triclosan-coa-
ted Polyglactin 910 antibacterial activity in wound clo-
sure after cerebrospinal fluid shunt surgery in humans
reduced the incidence of shunt infections22.
Justinger and others tested triclosan coated poly-
glactin 910 activity to prevent abdominal incisional site
infections. The study included all abdominal operation
performed through midline incisions. They found a re-
duction of poorly healing wounds after abdominal sur-
gery and a shorter hospitalization period in patients
whose incisions were closed with triclosan coated poly-
glactin 91015.
It is important to notice that recent Vicryl* Plus stud-
ies did not observe the effect of the suture on inflamma-
tory biochemical parameters, especially on PCT levels,
which are increased during inflammation and could be
used, as CRP or leukocyte levels are, as an inflammation
marker. In this current study the systemic inflammatory
response was measured with wound complications, which
resulted in the finding that triclosan coated polyglactin
910 activity and prevention of abdominal wound infec-
tions were related. Patients closed with the triclosan
coated suture had a significantly shorter period of hospi-
talization, inflammation parameters were normalized in
significantly shorter period, and wound dehiscence, post-
operative incisional hernias, skin inflammation and wound
secretion were significantly reduced. Considering these
results, and previous in vitro and studies on animal mod-
els, it can be concluded that triclosan coated suture pres-
ents an opportunity to improve the postoperative wound
healing process.
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U^INAK ANTIMIKROBNOG TRIKLOSANOM PRESVU^ENOG [AVA, POLIGLAKTINA 910 (VICRYL*
PLUS) NA ZATVARENJE RANA TRBU[NE STJENKE NAKON KOLOREKTALNIH OPERACIJA
S A @ E T A K
Ova studija uspore|uje u~inak triklosanom presvu{enog poliglaktina 910 (Vicryl* Plus) s u~inkom poliglaktina 910
(Vicryl*) na cijeljenje trbu{nog zida u kolorektalnih bolesnika. U studiju je uklju~eno 184 bolesnika. U 91 bolesnika
trbu{ni zid je za{iven s Vicryl* Plus {avom, a 93 bolesnika s Vicryl* {avom. Promatrani su: demografska obilje`ja,
biokemijski upalni parametri, izgled rane, vrijeme hospitalizacije, poslijeoperacijske komplikacije rane te u~estalost
poslijeoperacijskih hernija. U Vicryl* Plus grupi uo~eno je kra}e vrijeme boravka bolesnika u bolnici (13,2±1,3 dana;
naprema 21,4±2,8) Tako|er je u Vycril * Plus grupi uo~ena normalizacija upalnih parametara do normalnih vrijednosti
unutar prvog poslijeoperacijskog tjedna, dok su te vrijednosti u Vycril grupi ostale povi{ene. U Vycril*Plus grupi 4
bolesnika je imalo infekciju rane, 7 bolesnika je imalo upalnu reakciju na ko`ne {ave. Zapa`ena je jedna dehicenca rane.
U Vicryl* grupi 12 bolesnika je imalo infekciju rane,14 bolesnika je imalo upalnu reakciju na ko`ne {ave, a u 7 bolesnika
je uo~ena dehiscence rane. Zatvaranje trbu{nog zida Vicryl*Plus {avovima smanjuje u~estalost poslijeoperacijskih kom-
plikacija rane, skra}uje vrijeme boravka u bolnici te je povezana s brim padom upalnih laboratorijskih parameta do
normalnih vrijednosti.
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